Literature DB >> 16859314

A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone.

Hong Liang1, Xing Wu, Lynn J Guziec, Frank S Guziec, Kimberly K Larson, Jennifer Lang, Jack C Yalowich, Brian B Hasinoff.   

Abstract

A series of 13 anthrapyrazole compounds that are analogues of piroxantrone and losoxantrone were synthesized, and their cell growth inhibitory effects, DNA binding, topoisomerase IIalpha mediated (EC 5.99.1.3) cleavage of DNA, and inhibition of DNA topoisomerase IIalpha decatenation catalytic activities were determined. Cell growth inhibitory activity was well-correlated with DNA binding, suggesting that these compounds may act by targeting DNA. However, cell growth inhibition was not well-correlated with the inhibition of topoisomerase IIalpha catalytic activity, suggesting that these anthrapyrazoles did not act solely by inhibiting the catalytic activity of topoisomerase II. Most of the analogues were able to induce DNA cleavage, and thus, it was concluded that they acted, at least in part, as topoisomerase II poisons. Structure-based three-dimensional quantitative structure-activity analyses (3D-QSAR) were carried out on the aligned structures of the anthrapyrazoles docked into DNA using comparative molecular field analysis (CoMFA) and comparative molecular similarity index (CoMSIA) analyses in order to determine the structural features responsible for their activity. Both CoMFA and CoMSIA yielded statistically significant models upon partial least-squares analyses. The 3D-QSAR analyses showed that hydrogen-bond donor interactions and electrostatic interactions with the protonated amino side chains of the anthrapyrazoles led to high cell growth inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16859314     DOI: 10.1021/ci060056y

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  11 in total

1.  Cadmium is a catalytic inhibitor of DNA topoisomerase II.

Authors:  Xing Wu; Jack C Yalowich; Brian B Hasinoff
Journal:  J Inorg Biochem       Date:  2011-02-26       Impact factor: 4.155

2.  Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents.

Authors:  Rui Zhang; Xing Wu; Lynn J Guziec; Frank S Guziec; Gaik-Lean Chee; Jack C Yalowich; Brian B Hasinoff
Journal:  Bioorg Med Chem       Date:  2010-04-18       Impact factor: 3.641

3.  The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.

Authors:  Jack C Yalowich; Xing Wu; Rui Zhang; Ragu Kanagasabai; Marisa Hornbaker; Brian B Hasinoff
Journal:  Biochem Pharmacol       Date:  2012-04-04       Impact factor: 5.858

4.  Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents.

Authors:  Rui Zhang; Xing Wu; Jack C Yalowich; Brian B Hasinoff
Journal:  Bioorg Med Chem       Date:  2011-10-14       Impact factor: 3.641

5.  A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II.

Authors:  Gaik-Lean Chee; Jack C Yalowich; Andrew Bodner; Xing Wu; Brian B Hasinoff
Journal:  Bioorg Med Chem       Date:  2009-11-27       Impact factor: 3.641

6.  Development of purely structure-based pharmacophores for the topoisomerase I-DNA-ligand binding pocket.

Authors:  Malgorzata N Drwal; Keli Agama; Yves Pommier; Renate Griffith
Journal:  J Comput Aided Mol Des       Date:  2013-12-01       Impact factor: 3.686

7.  Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F.

Authors:  Kimberley A O'Hara; Xing Wu; Daywin Patel; Hong Liang; Jack C Yalowich; Nan Chen; Valerie Goodfellow; Otunola Adedayo; Gary I Dmitrienko; Brian B Hasinoff
Journal:  Free Radic Biol Med       Date:  2007-07-13       Impact factor: 7.376

8.  Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.

Authors:  Brian B Hasinoff; Xing Wu; Daywin Patel; Ragu Kanagasabai; Soumendrakrishna Karmahapatra; Jack C Yalowich
Journal:  J Pharmacol Exp Ther       Date:  2015-12-11       Impact factor: 4.030

9.  The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.

Authors:  Brian B Hasinoff; Hong Liang; Xing Wu; Lynn J Guziec; Frank S Guziec; Kyle Marshall; Jack C Yalowich
Journal:  Bioorg Med Chem       Date:  2008-01-26       Impact factor: 3.641

10.  Identifying new topoisomerase II poison scaffolds by combining publicly available toxicity data and 2D/3D-based virtual screening.

Authors:  Anna Lovrics; Veronika F S Pape; Dániel Szisz; Adrián Kalászi; Petra Heffeter; Csaba Magyar; Gergely Szakács
Journal:  J Cheminform       Date:  2019-11-09       Impact factor: 5.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.